Evidence map›Paper›PMID 40671697›Full record

ArticleClinical kidney journal2025

Loop diuretics in anuric hemodialysis patients for the clearance of protein-bound uremic toxins.

Didier Sánchez-Ospina, Maria Romero-Cote, Lucia Criado-Bellido, Maria Isabel Saez-Calero, Badawi Hijazi-Prieto, Sandra Delgado-Cuesta, Francisco Herrera-Gómez, Maddalen Mujika-Marticorena, Emilio Gonzalez-Parra, Maria Jesus Izquierdo-Ortiz and 1 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Ten tips for the first hemodialysis sessions.Clinical kidney journal · 2026
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Didier Sánchez-OspinaServicio Análisis Clínicos, Hospital Universitario de Burgos, Burgos, Spain.
Maria Romero-CoteLaboratory of Renal pathology and diabetes, IIS-Fundación Jiménez Díaz, Autonoma University, Madrid, Spain.
Lucia Criado-BellidoDepartment of Nephrology and Hypertension, IIS-Fundación Jiménez Díaz, Universidad Autonoma de Madrid, Madrid, Spain.
Maria Isabel Saez-CaleroDepartment of Nephrology, Burgos University Hospital, Burgos, Spain.
Badawi Hijazi-PrietoDepartment of Nephrology, Burgos University Hospital, Burgos, Spain.
Sandra Delgado-CuestaServicio Análisis Clínicos, Hospital Universitario de Burgos, Burgos, Spain.
Francisco Herrera-GómezDepartment of Nephrology, Burgos University Hospital, Burgos, Spain.
Maddalen Mujika-MarticorenaServicio Análisis Clínicos, Hospital Universitario de Burgos, Burgos, Spain.
Emilio Gonzalez-ParraLaboratory of Renal pathology and diabetes, IIS-Fundación Jiménez Díaz, Autonoma University, Madrid, Spain.
Maria Jesus Izquierdo-OrtizDepartment of Nephrology, Burgos University Hospital, Burgos, Spain.
Sebastián Mas-FontaoLaboratory of Renal pathology and diabetes, IIS-Fundación Jiménez Díaz, Autonoma University, Madrid, Spain.ORCID https://orcid.org/0000-0001-6604-3327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In chronic kidney disease, the accumulation of protein-bound uremic toxins (PBUTs), such as hippuric acid (HA), p-cresyl sulfate (PCS) and indoxyl sulfate (IS), contributes to systemic toxicity and organ dysfunction. These toxins bind to plasma proteins, primarily albumin, rendering them resistant to clearance by conventional dialysis. This study hypothesizes that loop diuretics, particularly torasemide and furosemide, can displace PBUTs from their albumin-binding sites, increasing their free fraction and enhancing their removal during hemodialysis. Methods: This pilot multicenter crossover study included 17 anuric hemodialysis patients recruited from two hospitals. Participants underwent sequential treatment with furosemide and torasemide, each phase separated by a 1-week washout period. Plasma concentrations of HA, PCS and IS were measured pre- and post-dialysis during baseline (no diuretics) and diuretic treatment phases using high-performance liquid chromatography coupled with tandem mass spectrometry. Changes in pre- and post-dialysis toxin levels were evaluated across treatment phases. Repeated measures analysis of variance assessed the effect of each diuretic treatment on toxin levels and clearance rates. Results: Both loop diuretics increased the free fraction and clearance of PBUTs compared with baseline. Torasemide demonstrated higher efficacy in enhancing the clearance of HA (76.8%) compared with furosemide (63.2%) and baseline (57.3%). For PCS, furosemide achieved greater reductions (66.3%) than torasemide (61.8%) and baseline (24%). Indoxyl sulfate clearance increased significantly with both diuretics (59.1% for furosemide and 58.8% for torasemide) compared with baseline (26.2%). Conclusion: This study demonstrates that loop diuretics, especially torasemide, can enhance the clearance of PBUTs during hemodialysis. Their use mobilizes PBUTs from tissue stores and increases their dialyzability. These findings warrant further investigation in larger, long-term studies to validate the efficacy and clinical benefits of this approach.

Indexed as

dialysisloop diureticsprotein-bound uremic toxinstorasemideuremia

Identifiers

PMID40671697
PMCPMC12264483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.